New Daily Persistent Headache Biomarkers Study — NDPH  

New Daily Persistent Headache Clinical Trial

Official title: Plasma Calcitonin Gene-Related Peptide and Nerve Growth Factor Levels in New Daily Persistent Headache and Chronic Migraine to Identify Potential Biomarkers and Therapeutics Targets

Status Terminated

Clinical Trial Summary

New daily persistent headache is a debilitating syndrome which is seldom researched, poorly understood, and without effective treatments. Chronic migraine is a more common but similarly disabling disorder. The goal of this study is to evaluate the blood levels of two proteins involved with pain signaling; calcitonin gene-related peptide (CGRP) and nerve growth factor (NGF). CGRP levels are known to be elevated in chronic migraine, and recent phase 2 clinical trials suggest that treatments targeting CGRP are safe and effective for treatments for migraine. If CGRP levels are elevated in the blood of people with new daily persistent headache, future studies will be designed to evaluate whether treatments that target CGRP are effective in treating new daily persistent headache. If NGF levels are elevated in the blood of patients with new daily persistent headache and/or chronic migraine, future studies will be designed to evaluate whether treatments that target NGF antibodies (targeted treatments against NGF) are effective in treating NDPH and/or chronic migraine.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Headache
• New Daily Persistent Headache
• New Daily Persistent Headache (NDPH)

• NCT number: NCT04260087
• Study type: Observational
• Source: Albert Einstein College of Medicine
• Status: Terminated
• Start date: May 1, 2018
• Completion date: November 18, 2021